If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Director/PDMR Shareholding

19 May 2023 16:15

RNS Number : 0848A
Smith & Nephew Plc
19 May 2023
 

SMITH & NEPHEW PLC

 

19 May 2023

 

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2022 final dividend payment on 17 May 2023.

Date of Transaction

2023 - 05 - 17

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

Director / PDMR

Price

Volume

Aggregated information

Total Ordinary Share Holding following the transaction *

Total Ordinary Share Holding as a % of the Company's ISC following the transaction *

Helen Barraclough

(Group General Counsel and Company Secretary)

PDMR

£13.13964

406.16316

N/A Single Transaction

29,139.41087

0.00332%

Bradley Cannon

(Global Orthopaedics)

PDMR

£13.13964

365.26743

N/A Single Transaction

118,184.64237 (including 3,599.09977 in ADS')

0.01347%

Paul Connolly

(President Global Operations)

PDMR

£13.13964

102.08593

N/A Single Transaction

7,400.08593

0.00084%

Phil Cowdy

(Chief Corporate Development & Corporate Affairs Officer)

PDMR

£13.13964

195.14937

N/A Single Transaction

49,196.14246

0.00561%

Myra Eskes

(President APAC & Global Service)

PDMR

£13.13964

855.60779

N/A Single Transaction

62,021.97554

0.00707%

Simon Fraser

(President AWM and Global Commercial Operations)

PDMR

£13.13964

707.85737

N/A Single Transaction

51,311.72617

0.00585%

Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)

PDMR

£13.13964

54.14835

N/A Single Transaction

5,530.80779 (including 802.82972 in ADS')

0.00063%

Elga Lohler

(Chief HR Officer)

PDMR

£13.13964

285.19156

N/A Single Transaction

144,683.19156 (including 3,015.00000 in ADS')

0.01649%

Deepak Nath

(Chief Executive Officer)

Director

£13.13964

1,367.8228

N/A Single Transaction

99,151.82280

0.01130%

Vasant Padmanabhan

(President Research & Development)

PDMR

£13.13964

264.13931

N/A Single Transaction

100,353.13931

0.01143%

Alison Parkes

(Chief Compliance Officer)

PDMR

£13.13964

30.61803

N/A Single Transaction

4,679.11972 (including 1,040.32795 in ADS')

0.00053%

Scott Schaffner

(President Sports Medicine)

PDMR

£13.13964

763.54875

N/A Single Transaction

68,095.98048 (including 1,927.12679 in ADS')

0.00776%

 

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

 

 

Sarah Carne

Deputy Company Secretary

Smith & Nephew plc

 

Tel: +44 (0)1923 477100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFESELIALIV

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.